Navigation Links
Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
Date:9/23/2009

BERLIN, Sept. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer. The data were presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress in Berlin.

Jose Baselga, M.D., chairman and professor of medicine at Vall d'Hebron Institute of Oncology in Barcelona, scientific chairman of SOLTI and the principal investigator of this study, reported that patients receiving Nexavar plus capecitabine had a 74 percent improvement in the time they lived without their disease progressing compared to those who received the chemotherapy alone. The difference in median progression-free survival of Nexavar plus capecitabine versus capecitabine plus placebo was statistically significant, 6.4 months vs. 4.1 months (HR=.576, p=0.0006).

"Onyx and Bayer have built a strong foundation with Nexavar in treating unresectable liver cancer and advanced kidney cancer - both disease areas with a previously unmet treatment need," said Todd Yancey, M.D., vice president of clinical development at Onyx. "These new results signify another step in understanding the potential role of Nexavar in breast cancer."

The study evaluated Nexavar in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Overall, treatment with Nexavar plus capecitab
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
2. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
3. Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
6. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
7. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
8. More Sleep & Less Sex - A Losing Combination
9. Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
10. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
11. Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Stephen T. Greenberg, ... been nominated for the 10th consecutive year as one of ... Dr. Greenberg was also been nominated as the best provider ... also nominated as best Day Spa and best Laser Treatment ... December 14th and readers can vote for the contest once ...
(Date:10/19/2014)... OCTOBER 20, 2014 – The U.S. Government has ... treat Alzheimer,s disease by 2025. However, a workgroup ... the research milestones in the U.S. Government,s National ... in scope, increased in scale, and adequately funded ... series of proposals by the workgroup to enlarge ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 19, 2014 ... in demand for proton therapy despite the high-cost structure ... resulting in market growth. , Analysts forecast the Global ... CAGR of 9.50 percent over the period 2013-2018. According ... this market is the technological advances in medical diagnostics ...
Breaking Medicine News(10 mins):Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 2Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 3Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 4
... Offers a Simple Guide to Organizing Matters of Life ... are not organized with,medical information and life documents to ... Yorong in Lifetime Medical Organizer: A Simple,Guide to Organizing ... (published by AuthorHouse), the new book she wrote with,Richard ...
... Eight Alternatives to Exercise-Induced Asthma, INDIANAPOLIS, May ... chest pains while engaged in physical,activity, the default ... from,exercise-induced asthma (EIA). However, there are several other,explanations ... left untreated. A featured science session at the ...
... 10-K Extension ... ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires and ... to complete and file its fiscal 2008 Form,10-K with the Securities ...
... Water Beverage Presents Exercise Hydration Without the ... ... A new study presented at the,American College of Sports Medicine Annual ... beverage,developed by researchers for Scientific Food Solutions, LLC, for active,persons hydrates ...
... Paul Sierzenski, MD, RDMS, of Christiana Care Health System, ... care workers with immediate access to patient medical records ... that using radiofrequency devices that electronically contain a persons ... aid and reduce medical charges, two often incompatible goals. ...
... a new study, knowledge of potentially toxic household substances ... The results show that less than one-third of primary ... correctly estimate the toxicity of household poisons. The study ... Medicines 2008 Annual Meeting. , Led by Rika N. ...
Cached Medicine News:Health News:Lifetime Medical Organizer 2Health News:Pediatric Wheezing: If Not Asthma, Then What is It? 2Health News:Pediatric Wheezing: If Not Asthma, Then What is It? 3Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 2Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 3Health News:Zero-Calorie Aqua-Lyte(R) Hydrates as Well as Traditional Sports Drinks 2Health News:Zero-Calorie Aqua-Lyte(R) Hydrates as Well as Traditional Sports Drinks 3
(Date:10/16/2014)... Oct. 16, 2014 Eight finalists, all representing ... to present their proposals for a chance to compete ... Sheikh Zayed Institute Second Annual Pediatric Surgical Innovation ... on Friday, Oct. 24, 2014. Selected ... across the US and internationally, the finalists are: ...
(Date:10/16/2014)... , Oct. 16, 2014   NuVascular ... process to create new medical devices that help ... Inc., the company uses cutting-edge nanotechnology that would ... kidney diseases.  The platform technology ... result of $6.6 million in funding obtained from ...
(Date:10/16/2014)... -- Ninety percent of children and adults with acute ... failed to respond to standard therapies went into remission ... at the Perelman School of Medicine at the University ... New England Journal of Medicine . ... presented at the American Society of Hematology,s annual meeting ...
Breaking Medicine Technology:Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 2Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: